Latest Innovation News

Eden Innovations has landed a significant second order from Holcim Ecuador for its EdenCrete® Pz7 concrete additive, underscoring growing global interest in its low-carbon concrete solutions.

Westpac’s 1Q25 update reveals a resilient $1.7 billion net profit and strong loan growth despite margin pressures and economic headwinds.

The a2 Milk Company posted robust first-half FY25 results, lifting revenue by 10.1% and net profit by 7.6%, while introducing a dividend policy for the first time. Strong English label IMF sales and liquid milk growth underpin an upgraded full-year outlook.

The a2 Milk Company delivered solid first-half FY25 results with revenue up 10.1% and net profit rising 7.6%, driven by strong growth in China and the USA despite supply constraints and ANZ challenges. The company also declared its first-ever interim dividend and upgraded its full-year outlook.

The a2 Milk Company has reported robust first-half FY25 results, boosting full-year guidance and declaring its inaugural dividend, underscoring confidence in its growth trajectory.

Entyr Limited has extended the closing date for its capital raising offers to 3 March 2025, providing investors additional time to participate in new share and option subscriptions.

Osteopore Limited has drawn down A$2 million from the first tranche of its redeemable convertible notes, using the proceeds to repay existing loans and support ongoing business activities.

Carly Holdings Limited has agreed to merge its car subscription operations with Carbar Holdings in a $3.8 million deal, aiming to create a larger, more competitive player in Australia’s growing car subscription sector.

Neometals has received a second tranche of funding from EU-backed EIT RawMaterials, injecting nearly €0.5 million to advance its Finnish Vanadium Recovery Project amid ongoing financing efforts.

LGI Limited reports a solid H1 FY25 performance with modest revenue growth and increased EBITDA, driven by expanded biogas flows and carbon abatement activities. The company confirms a positive outlook with a 12-15% underlying EBITDA growth forecast for FY25.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.